Material Event (Form 8-K)

Item 8.01. Other Events.

On September 11, 2025, Lucid Diagnostics Inc. (the "Lucid Diagnostics"), a subsidiary of PAVmed Inc. (the "Company"), closed on the sale of 28,750,000 shares (the "Shares") of Lucid Diagnostics' common stock, at a price of $1.00 per share, in its previously announced underwritten offering to the public (the "Offering"). The Shares include 3,750,000 shares of Lucid Diagnostics' common stock subject to the underwriters' option, which was exercised in full at the closing. The net proceeds from the Offering, after deducting the underwriting discount and other estimated expenses of the Offering, are expected to be approximately $26.9 million. Lucid Diagnostics intends to use the net proceeds from the Offering for working capital and general corporate purposes.

The Offering was made pursuant to Lucid Diagnostics' existing shelf registration statement on Form S-3 (Registration No. 333-268560) and a prospectus supplement thereto dated September 10, 2025.

The Offering, including the related agreements, are described in more detail in the Current Reports on Form 8-K filed with the SEC by Lucid Diagnostics on September 10, 2025 and September 11, 2025, and such description is incorporated herein by reference.